Literature DB >> 31900301

Efficacy of JAK 1/2 inhibition in the treatment of diffuse non-scarring alopecia due to systemic lupus erythematosus.

Keisuke Maeshima1, Hirotaka Shibata2.   

Abstract

Entities:  

Keywords:  lupus nephritis; systemic lupus erythematosus; treatment

Mesh：

Substances：

Year:  2020        PMID： 31900301     DOI： 10.1136/annrheumdis-2019-216571

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  5 in total

1.  Case Report: Reversal of Long-Standing Refractory Diffuse Non-Scarring Alopecia Due to Systemic Lupus Erythematosus Following Treatment With Tofacitinib.

Authors:  Yu-Lan Chen; Li-Xiong Liu; Qin Huang; Xue-Ying Li; Xiao-Ping Hong; Dong-Zhou Liu
Journal:  Front Immunol       Date:  2021-04-14       Impact factor: 7.561

2.  Treating systemic lupus erythematosus in the 21st century: new drugs and new perspectives on old drugs.

Authors:  Guillermo Ruiz-Irastorza; George Bertsias
Journal:  Rheumatology (Oxford)       Date:  2020-12-05       Impact factor: 7.580

3.  Baricitinib Attenuates Autoimmune Phenotype and Podocyte Injury in a Murine Model of Systemic Lupus Erythematosus.

Authors:  Jaeseon Lee; Youngjae Park; Se Gwang Jang; Seung-Min Hong; Young-Seok Song; Min-Jun Kim; SeungYe Baek; Sung-Hwan Park; Seung-Ki Kwok
Journal:  Front Immunol       Date:  2021-08-23       Impact factor: 7.561

Review 4.  Why Do We Need JAK Inhibitors in Systemic Lupus Erythematosus?

Authors:  Patricia Richter; Anca Cardoneanu; Alexandra Maria Burlui; Luana Andreea Macovei; Ioana Bratoiu; Oana Nicoleta Buliga-Finis; Elena Rezus
Journal:  Int J Mol Sci       Date:  2022-10-04       Impact factor: 6.208

Review 5.  Advancements in the Treatment of Cutaneous Lupus Erythematosus and Dermatomyositis: A Review of the Literature.

Authors:  Kareem G Elhage; Raymond Zhao; Mio Nakamura
Journal:  Clin Cosmet Investig Dermatol       Date:  2022-09-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.